Biotechnology
Immunotherapy
Unitedstates
Development
Autoimmune
Personalized
Stock
Warrants
M&A Advisory
Lazard
Full Credential Description
Opexa Therapeutics, Inc.. United States. Announced Date 08/02/2011. Closed Date 11/02/2011. Deal value: $9m. Underwritten registered direct offering of common stock and warrants. Industry: Opexa Therapeutics, Inc. is a biotechnology company focused on developing personalized immunotherapy treatments for autoimmune diseases.